Clozapine in the Time of COVID-19
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Clozapine is the most effective antipsychotic for treatment resistant schizophrenia but adverse reactions to clozapine include neutropenia. The current COVID-19 pandemic may raise specific concerns for clinicians prescribing clozapine for patients who need it. We report on two actively psychotic patients with treatment resistant schizophrenia who required admission to our inner-London acute psychiatric unit during the COVID-19 pandemic and who were treated with clozapine. One was a young patient who developed COVID-19 symptoms and tested positive for the SARS-CoV-2 virus while receiving clozapine and the other was an aging man who tested negative for the SARS-CoV-2 virus but had contact with COVID-19 during initiation of clozapine treatment. Both responded to clozapine treatment and were safely discharged from hospital without any complication. These cases suggest that, in the absence of complications, exposure to COVID-19 per se and the onset of mild symptoms in those infected may not warrant withdrawal or postponement of clozapine treatment when this is indicated.
Abstract
Clozapine is the most effective antipsychotic for treatment resistant schizophrenia but adverse reactions to clozapine include neutropenia. The current COVID-19 pandemic may raise specific concerns for clinicians prescribing clozapine for patients who need it. We report on two actively psychotic patients with treatment resistant schizophrenia who required admission to our inner-London acute psychiatric unit during the COVID-19 pandemic and who were treated with clozapine. One was a young patient who developed COVID-19 symptoms and tested positive for the SARS-CoV-2 virus while receiving clozapine and the other was an aging man who tested negative for the SARS-CoV-2 virus but had contact with COVID-19 during initiation of clozapine treatment. Both responded to clozapine treatment and were safely discharged from hospital without any complication. These cases suggest that, in the absence of complications, exposure to COVID-19 per se and the onset of mild symptoms in those infected may not warrant withdrawal or postponement of clozapine treatment when this is indicated.
참고문헌 (10)
- Zunyou Wu, "Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323(13), pp.1239~ (2020), American Medical Association (AMA)[DOI]
- Chaolin Huang, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", The Lancet, 395(10223), pp.497~506 (2020), Elsevier BV[DOI]
- Vincent JL, "Understanding pathways to death in patients with COVID-19", Lancet Respir Med, 8, pp.430~432 (2020)
- Liu NH, "Excess mortality in persons with severe mental disorders : a multilevel intervention framework and priorities for clinical practice, policy and research agendas", World Psychiatry, 16, pp.30~40 (2017)
- Myles N, "Meta-analysis examining the epidemiology of clozapine-associated neutropenia", Acta Psychiatr Scand, 138, pp.101~109 (2018)
- Salamone S, "Point of care testing for clozapine", 32nd ECNP Congress (2019)
- Tian-Mei Si, "Use of Clozapine for the Treatment of Schizophrenia: Findings of the 2006 Research on the China Psychotropic Prescription Studies", Clinical Psychopharmacology and Neuroscience, 10(2), pp.99~104 (2012), 대한정신약물학회[DOI]
- Kane JM, "Factors which can make patients difficult to treat", Br J Psychiatry Suppl, (31), pp.10~14 (1996)
- Thien K, "Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder : a literature review", Early Interv Psychiatry, 13, pp.18~23 (2019)
- Siskind D, "Consensus statement on the use of clozapine during the COVID-19 pandemic", J Psychiatry Neurosci, 45, pp.200061~ (2020)